VESANOID 10 MG
TRETINOIN : 10 MG · DIN 02145839 · CHEPLAPHARM ARZNEIMITTEL GMBH
Health Canada status: MARKETED
What is VESANOID?
VESANOID 10 MG contains TRETINOIN : 10 MG. It is listed in the Health Canada Drug Product Database under DIN 02145839, held by CHEPLAPHARM ARZNEIMITTEL GMBH, supplied as CAPSULE for ORAL administration. Health Canada currently lists it as marketed, status dated 21-Oct-2013. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is VESANOID used for?
Induction of remission in acute promyelocytic leukemia (APL; FAB classification AML-M3). Includes previously untreated, relapsed, or refractory patients.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02145839 |
|---|---|
| Brand name | VESANOID |
| Generic / active ingredient | TRETINOIN : 10 MG |
| Manufacturer | CHEPLAPHARM ARZNEIMITTEL GMBH |
| Strength | 10 MG |
| Dosage form | CAPSULE |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | L01XF01 TRETINOIN |
| AHFS class | 10:00.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 21-Oct-2013 |
| Original market date | 1995-12-31 00:00:00 |
How is it administered?
45 mg/m2 daily divided into two equal doses. Continue for 30-90 days until remission. Swallow whole with water, preferably with a meal.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in provided text (section 11 mentioned in TOC but text cuts off). Standard practice is 15-30°C.
How is it supplied?
Bottles of 100 capsules.
Contraindications
Hypersensitivity to tretinoin or ingredients; pregnancy and nursing mothers; use with vitamin A, tetracyclines, or other retinoids.
Warnings and precautions
Serious risk of teratogenicity; Differentiation Syndrome (may be fatal); Hyperleukocytosis; Retinoic Acid Syndrome; Intracranial hypertension; Thrombosis risk.
What can be used instead?
Other Canadian products sharing ATC code L01XF01 TRETINOIN. 2 of 2 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| JAMP TRETINOIN | 10 MG | CAPSULE | JAMP PHARMA CORPORATION | MARKETED | DIN 02520036 |
Who else supplies TRETINOIN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. TRETINOIN appears in 1362 registered pack listings across 7 markets, published on 6 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.